Loading...
Immune checkpoint inhibitors improve response, progression-free survival, and overall survival when added to first-line chemotherapy in patients with esophagogastric adenocarcinoma. Investigators now report results of KEYNOTE-585, an industry-sponsored, international, phase 3 trial evaluating the addition of pembrolizumab to pre- and postoperative chemotherapy in patients with clinical stage T3–4 or node-positive resectable gastric cancer.
A main cohort of 804 patients were randomized to receive either pembrolizumab (200 mg) or placebo combined with chemotherapy — investigator's choice of capecitabine plus cisplatin or a 5-day infusion of fluorouracil (FU) plus cisplatin — for 3 cycles before surgery and 3 cycles after, followed by 11 cycles…